Discovery and Development of Orally Active RSV Fusion Inhibitors

Antiviral Drugs: From Basic Discovery through Clinical Trials

Volumn , Issue , 2011, Pages 353-366

  Meanwell, Nicholas A ^a   Cianci, Christopher W ^a   Krystal, Mark R ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antiviral activity associated with RSV inhibitors incorporating acidic side chains; Orally active RSV fusion inhibitors RSV, of Paramyxovirus family of viruses; Structure activity relationship (SAR) evolution post BMS 433771

Indexed keywords

EID: 84885975849     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470929353.ch25     Document Type: Chapter

References (76)

1. Chanock, R.; Roizman, B.; Myers, R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). Am. J. Hyg. 1957, 66, 281-290.
2. Glezen, W. P., et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child 1986, 140, 543-546.
3. Holberg, C. J., et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am. J. Epidemiol. 1991, 133, 1135-1151.
4. Mills, J.Management of respiratory syncytial virus infections. Adv. Exp. Med. Biol. 1996, 394, 163-174.
5. Garcia, R., et al. Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients. Infect. Control Hosp. Epidemiol. 1997, 18, 412-416.
6. Murry, A. R.; Dowell, S. F. Respiratory syncytial virus: not just for kids. Hosp. Pract. 1997, Jul. 15; 87-88.
7. Hall, C. B., et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J .Med. 2009, 360, 588-598.
8. Georgescu, G.; Chemaly, R. F. Palivizumab: Where to from here? Expert Opin. Biol. Ther. 2009, 9, 139-147.
9. Madaan, A. Motaviizumab; humanized anti-RSV monoclonal antibody prevention of RSV infection. Drugs Future 2008, 33, 203-205.
10. Power, U. F. Respiratory syncytial virus (RSV) vaccines: two steps back for one leap forward. J. Clin. Virol. 2008, 41, 38-44.
11. Moyse, E., et al. Viral RNA in middle ear mucosa and exudates in patients with chronic otitis media with effusion. Arch. Otolaryngol. Head Neck Surg. 2000, 126, 1105-1110.
12. Heikkinen, T.; Thint, M.; Chonmaitree, T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N. Engl. J. Med. 1999, 340, 260-264.
13. Chonmaitree, T., et al. Viral upper respiratory tract infection and otitis media complication in young children. Clin. Infect. Dis. 2008, 46, 815-823.
14. Sigurs N. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am. J. Respir. Crit. Care Med. 2001, 163, S2-S6.
15. Stensballe, L.G., et al.Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J. Allergy Clin. Immunol. 2009, 123, 398-340.
16. Faber, T. E.; Kimpen, J. L.; Bont, L. J. Respiratory syncytial virus bronchiolitis: prevention and treatment. Expert Opin. Pharmacother. 2008, 9, 2451-2458.
17. Ramaswamy, M.; Groskreutz, D. J.; Look, D. C. Recognizing the importance of respiratory syncytial virus in chronic obstructive pulmonary disease. COPD 2009, 6, 64-75.
18. Mohapatra, S. S.; Boyapalle, S. Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clin. Microbiol. Rev. 2008, 21, 495-504.
19. Falsey, A. R.; Walsh, E. E. Respiratory syncytial virus infection in adults. Clin. Microbiol. Rev. 2000, 13, 371-384.
20. Falsey, A. R., et al. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 2005, 352, 1749-1759.
21. Murata, Y.; Falsey, A. R. Respiratory syncytial virus infection in adults. Antiviral Ther. 2007, 12, 659-670.
22. Murata, Y. Respiratory syncytial virus infection in adults. Curr. Opin. Pulm. Med. 2008, 14, 235-240.
23. Englund, J. A., et al. Respiratory syncytial virus infection in immunocompromised adults. Ann. Intern. Med. 1988, 109, 203-208.
24. Harrington, R. D., et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J. Infect. Dis. 1992, 165, 987-993.
25. Thompson, W. W., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. J. Amer. Med. Assoc. 2003, 289, 179-186.
26. Osterweil, D.;Norman, D. An outbreak of an influenza-like illness in a nursing home. J. Am.Geriatr. Soc. 1990, 38, 659-662.
27. Hall, W. J.; Hall, C. B.; Speers, D. M. Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies. Ann. Intern.Med. 1978, 88, 203-205.
28. Falsey, A. R. Respiratory syncytial virus infection in adults. Semin. Respir. Crit. Care Med. 2007, 28, 171-181.
29. Pauwels, R., et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20, 309-321.
30. Cianci, C., et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob. Agents Chemother. 2004, 48, 413-422.
31. Pagani, F.; Sparatore, F. Benzotriazolylalkyl benzimidazoles and their dialkylaminoalkyl derivatives. Boll. Chim. Farm. 1965, 104, 427-431.
32. Paglietti, G.; Boido, V.; Sparatore, F. Dialkylaminoalkylbenzimidazoles of pharmacological interest: IV. Farm. Ed. Sci. 1975, 30, 505-511.
33. Johnson, S., et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997, 176, 1215-1224.
34. Kilby, J. M., et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 1988, 4, 1302-1307.
35. Yu, K.-L., et al. Fundamental structure-activity relationships associated with a new structural class of respiratory syncytial virus inhibitor. Bioorg. Med. Chem. Lett. 2003, 13, 2141-2144.
36. Meanwell, N. A., et al. The regiospecific functionalization of 1,3-dihydro-2H-benzimidazol-2-one and structurally related cyclic urea derivatives. J. Org. Chem. 1995, 60, 1565-1582.
37. Yu, K.-L., et al. Respiratory syncytial virus fusion inhibitors: 2. Benzimidazol-2-one derivatives. Bioorg. Med. Chem. Lett. 2004, 14, 1133-1137.
38. Byrd L. G.; Prince, G. A. Animal models of respiratory syncytial virus infection. Clin. Infect. Dis. 1997, 25, 1363-1368.
39. Domachowske, J. B.;Bonville,C.A.; Rosenberg,H. F.Animal models for studying respiratory syncytial virus infection and its long term effects on lung function. Pediatr. Infect. Dis. J. 2004, 23, S228-S234.
40. Prince, G. A., et al. Respiratory syncytial virus infection in inbred mice. Infect. Immun. 1979, 26, 764-766.
41. Sudo, K., et al. Mouse model of respiratory syncytial virus infection to evaluate antiviral activity in vivo. Antiviral Chem. Chemother. 1999, 10, 135-139.
42. Kong, X., et al. An immunocompromised BALB/c mouse model for respiratory syncytial virus infection. Virol. J. 2005, 2, 3-11.
43. Prince, G. A., et al. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am. J. Pathol. 1978, 93, 771-791.
44. Prince, G. A., et al. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res. 1985, 3, 193-206.
45. Prince, G. A.; Horswood, R. L.; Chanock, R. M. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J. Virol. 1985, 55, 517-520.
46. Grubbs, S. T.; Kania, S. A.; Potgieter, L. N. Prevalence of ovine and bovine respiratory syncytial virus infections in cattle determined with a synthetic peptide-based immunoassay. J. Vet. Diagn. Invest. 2001, 13, 128-132.
47. Huntley, C. C., et al. RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob. Agents Chemother. 2002, 46, 841-847.
48. Graham, B. S.; Rutigliano, J. A.; Johnson, T. R. Respiratory syncytial virus immunobiology and pathogenesis. Virology 2002, 297, 1-7.
49. Wyde, P. R.;Wilson, S. Z.; Petrella, R.; Gilbert, B. E. Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice. Antiviral Res. 1987, 7, 211-220.
50. Wilson, S. Z., et al. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob. Agents Chemother. 1980, 17, 642-648.
51. Yu, K.-L., et al. Respiratory syncytial virus fusion inhibitors: 3. Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo. Bioorg. Med. Chem. Lett. 2006, 16, 1115-1122.
52. Yu, K.-L., et al. Respiratory syncytial virus fusion inhibitors. 4. Optimization for orally bioavailability. Bioorg. Med. Chem. Lett. 2007, 17, 895-901.
53. Cianci, C., et al. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob. Agents Chemother. 2004, 48, 2448-2454.
54. Wyde, P. R. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res. 1998, 39, 63-79.
55. Dischino, D. D., et al. Development of a photoaffinity label for respiratory syncytial inhibitors. J. Radiolabelled Cpd. Radiopharm. 2003, 46, 1105-1116.
56. Cianci, C., et al. Targeting a binding pocket within the trimerof-hairpins: small-molecule inhibition of viral fusion. Proc. Natl. Acad. Sci. USA 2004, 101, 15046-15051.
57. Earp, L. J., et al. The many mechanisms of viral membrane fusion proteins. Curr. Top. Microbiol. Immunol. 2005, 285, 25-66.
58. Matthews, J. M., et al. The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil. J. Virol. 2000, 74, 5911-5920.
59. Zhao, X., et al. Structural characterization of the human respiratory syncytial virus fusion protein core. Proc. Natl. Acad. Sci. USA 2000, 97, 14172-14177.
60. Provencal,D. P., et al.Development of an efficient and scalable process of a respiratory syncytial virus inhibitor. Org. Process Res. Dev. 2004, 8, 903-908.
61. Wang, X. A., et al. Respiratory syncytial virus fusion inhibitors: 5. Optimization of benzimidazole substitution patterns towards derivatives with improved activity. Bioorg. Med. Chem. Lett. 2007, 17, 4592-4598.
62. Combrink, K. D., et al. Respiratory syncytial virus fusion inhibitors: 6. An examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety. Bioorg. Med. Chem. Lett. 2007, 17, 4784-4790.
63. Sin, N., et al. Respiratory syncytial virus fusion inhibitors: 7. Structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg. Med. Chem. Lett. 2009, 19, 4857-4862.
64. Tidwell, R. R.; Geratz, J. D.; Dubovi, E. J. Aromatic amidines. Comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin, and trypsin. J. Med. Chem. 1983, 26, 294-298.
65. Tidwell, R. R.; Geratz, J. D.; Dubovi, E. J. Inhibition of respiratory syncytial virus by bis(5-amidino-2-benzimidazolyl)methane. Virology 1980, 103, 502-504.
66. Dubovi, E. J., et al. Inhibition of respiratory syncytial virus-host cell interactions by mono-and diamidines. Antimicrob. Agents Chemother. 1981, 19, 649-656.
67. Dubovi, E. J.; Geratz, J. D.; Tidwell, R. R. Enhancement of respiratory syncytial virus-induced cytopathology by trypsin, thrombin, and plasmin. Infect. Immun. 1983, 40, 351-358.
68. Tidwell, R. R., et al. Suppression of respiratory syncytial virus infection in cotton rats by bis(5-amidino-2-benzimidazolyl)methane. Antimicrob. Agents Chemother. 1984, 26, 591-593.
69. Douglas, J. L., et al. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob. Agents Chemother. 2005, 49, 2460-2466.
70. Douglas, J. L., et al. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J. Virol. 2003, 77, 5054-5064.
71. Andries, K., et al. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res. 2003, 60, 209-219.
72. Bonfanti, J.-F., et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate: improving the pharmacokinetic profile using the structure-property relationship. J. Med. Chem. 2007, 50, 4572-4584.
73. Bonfanti, J.-F., et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate: 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J. Med. Chem. 2008, 51, 875-896.
74. Bonfanti, J.-F. et al. Discovery of TMC-353121, a novel RSV fusion inhibitor with potent in vitro and in vivo activity. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Sept. 17-20, 2007. Poster F1-950.
75. Wyde, P. R., et al. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res. 2005, 68, 18-26.
76. Wyde, P. R., et al. Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Res. 2003, 60, 221-231.